Insulin enhances the effect of nitric oxide at inhibiting neointimal hyperplasia in a rat model of type 1 diabetes

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 299, Issue 3, 2010, Pages

  Varu, Vinit N ^a,b   Ahanchi, Sadie S ^a,b   Hogg, Melissa E ^a   Bhikhapurwala, Hussein A ^a   Chen, Amy ^a   Popowich, Daniel A ^a   Vavra, Ashley K ^a   Martinez, Janet ^a   Jiang, Qun ^a   Saavedra, Joseph E ^c   Hrabie, Joseph A ^c   Keefer, Larry K ^d   Kibbe, Melina R ^a,e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Arterial injury; Proliferation; Vascular smooth muscle cells

Indexed keywords

3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; DISODIUM 1 [(2 CARBOXYLATO)PYRROLIDIN 1 YL]DIAZEN 1 IUM 1,2 DIOLATE; GLUCOSE; INSULIN GLARGINE; NITRIC OXIDE; NITRIC OXIDE DONOR; UNCLASSIFIED DRUG; INSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY INJURY; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; VASCULAR SMOOTH MUSCLE; ANALYSIS OF VARIANCE; ANIMAL; AORTA; CAROTID ARTERY; CELL CULTURE; DRUG EFFECTS; DRUG INTERACTION; EXPERIMENTAL DIABETES MELLITUS; FLOW CYTOMETRY; HYPERPLASIA; INTIMA; METABOLISM; PATHOLOGY; SMOOTH MUSCLE FIBER;

ANALYSIS OF VARIANCE; ANIMALS; AORTA; CAROTID ARTERIES; CELL DEATH; CELL PROLIFERATION; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG INTERACTIONS; FLOW CYTOMETRY; HYPERPLASIA; INSULIN; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE; RATS; TUNICA INTIMA;

EID: 77956681979     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01234.2009     Document Type: Article

References (46)

1. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type-Ii Diabetes (Va Csdm). Results of the Feasibility Trial. Diabetes Care 18: 1113-1123, 1995.
2. Ahanchi SS, Varu VN, Tsihlis ND, Martinez J, Pearce CG, Kapadia MR, Jiang Q, Saavedra JE, Keefer LK, Hrabie JA, Kibbe MR. Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome. Am J Physiol Heart Circ Physiol 295: H2388-H2398, 2008.
3. Avogaro A, de Kreutzenberg SV, Fadini GP. Oxidative stress and vascular disease in diabetes: is the dichotomization of insulin signaling still valid? Free Radic Biol Med 44: 1209-1215, 2008.
4. Bakken AM, Palchik E, Hart JP, Rhodes JM, Saad WE, Davies MG. Impact of diabetes mellitus on outcomes of superficial femoral artery endoluminal interventions. J Vasc Surg 46: 946-958, 2007.
5. Barbato JE, Zuckerbraun BS, Overhaus M, Raman KG, Tzeng E. Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance and the metabolic syndrome. Am J Physiol Heart Circ Physiol 289: H228-H236, 2005. (Pubitemid 40934104)
6. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287: 2570-2581, 2002.
7. Boyne MS, Saudek CD. Effect of insulin therapy on macrovascular risk factors in type 2 diabetes. Diabetes Care 22: C45-C53, 1999.
8. Bredt DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem 63: 175-195, 1994. (Pubitemid 2109107)
9. Carmody BJ, Arora S, Wakefield MC, Weber M, Fox CJ, Sidawy AN. Progesterone inhibits human infragenicular arterial smooth muscle cell proliferation induced by high glucose and insulin concentrations. J Vasc Surg 36: 833-838, 2002.
10. Chaux A, Ruan XM, Fishbein MC, Ouyang Y, Kaul S, Pass JA, Matloff JM. Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation. J Thorac Cardiovasc Surg 115: 604-612, 1998.
11. Cruzado M, Risler N, Castro C, Ortiz A, Ruttler ME. Proliferative effect of insulin on cultured smooth muscle cells from rat mesenteric resistance vessels. Am J Hypertens 11: 54-58, 1998.
12. Davies MG, Dalen H, Kim JH, Barber L, Svendsen E, Hagen PO. Control of accelerated vein graft atheroma with the nitric oxide precursor: L-arginine. J Surg Res 59: 35-42, 1995.
13. DeRosa F, Kibbe MR, Najjar SF, Citro ML, Keefer LK, Hrabie JA. Nitric oxide-releasing fabrics and other acrylonitrile-based diazeniumdiolates. J Am Chem Soc 129: 3786-3787, 2007. (Pubitemid 46595475)
14. Dubey RK, Jackson EK, Lüscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest 96: 141-149, 1995.
15. Eckardt K, May C, Koenen M, Eckel J. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 50: 2534-2543, 2007.
16. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schomig A. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 32: 1866-1873, 1998.
17. Fleser PS, Nuthakki VK, Malinzak LE, Callahan RE, Seymour ML, Reynolds MM, Merz SI, Meyerhoff ME, Bendick PJ, Zelenock GB, Shanley CJ. Nitric oxide-releasing biopolymers inhibit thrombus formation in a sheep model of arteriovenous bridge grafts. J Vasc Surg 40: 803-811, 2004.
18. Fujita N, Furukawa Y, Du J, Itabashi N, Fujisawa G, Okada K, Saito T, Ishibashi S. Hyperglycemia enhances VSMC proliferation with NF-kappaB activation by angiotensin II and E2F-1 augmentation by growth factors. Mol Cell Endocrinol 192: 75-84, 2002.
19. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83: 1774-1777, 1989. (Pubitemid 19124139)
20. Gunther S, Alexander RW, Atkinson WJ, Gimbrone MA. Functional angiotensin-II receptors in cultured vascular smooth-muscle cells. J Cell Biol 92: 289-298, 1982.
21. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 84: 9265-9269, 1987.
22. Indolfi C, Torella D, Cavuto L, Davalli AM, Coppola C, Esposito G, Carriero MV, Rapacciuolo A, Di Lorenzo E, Stabile E, Perrino C, Chieffo A, Pardo F, Chiariello M. Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats. Circulation 103: 2980-2986, 2001.
23. Jonas M, Edelman ER, Groothuis A, Baker AB, Seifert P, Rogers C. Vascular neointimal formation and signaling pathway activation in response to stent injury in insulin resistant and diabetic animals. Circ Res 97: 725-733, 2005.
24. Kapadia MR, Chow LW, Tsihlis ND, Ahanchi SS, Hrabie JA, Murar J, Martinez J, Popowich DA, Jiang Q, Hrabie JA, Saavedra JE, Keefer LK, Hulvat JF, Stupp SI, Kibbe MP. Nitric oxide and nanotechnology: a novel approach to inhibit neointimal hyperplasia. J Vasc Surg 47: 173-182, 2008.
25. Kaul S, Cercek B, Rengstrom J, Xu XP, Molloy MD, Dimayuga P, Parikh AK, Fishbein MC, Nilsson J, Rajavashisth TB, Shah PK. Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB. J Am Coll Cardiol 35: 493-501, 2000.
26. Kibbe MR, Li J, Nie S, Watkins SC, Lizonova A, Kovesdi I, Simmons RL, Billiar TR, Tzeng E. Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate. J Vasc Surg 31: 1214-1228, 2000.
27. Kibbe MR, Tzeng E, Gleixner SL, Watkins SC, Kovesdi I, Lizonova A, Makaroun MS, Billiar TR, Rhee RY. Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. J Vasc Surg 34: 156-165, 2001.
28. Kown MH, Yamaguchi A, Jahncke CL, Miniati D, Murata S, Grunenfelder J, Koransky ML, Rothbard JB, Robbins RC. L-Arginine polymers inhibit the development of vein graft neointimal hyperplasia. J Thorac Cardiovasc Surg 121: 971-980, 2001.
29. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 88: 4651-4655, 1991. (Pubitemid 21914599)
30. Lee JS, Adrie C, Jacob HJ, Roberts JDJ, Zapol WM, Bloch KD. Chronic inhalation of nitric oxide inhibits neointimal formation after balloon-induced arterial injury. Circ Res 78: 337-342, 1996.
31. Marks DS, Vita JA, Folts JD, Keaney JFJ, Welch GN, Loscalzo J. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest 96: 2630-2638, 1995.
32. Masters KS, Lipke EA, Rice EE, Liel MS, Myler HA, Zygourakis C, Tulis DA, West JL. Nitric oxide-generating hydrogels inhibit neointima formation. J Biomater Sci Polym Ed 16: 659-672, 2005.
33. Narayan KM, Boyle J, Thompson T, Sorenson S, David W. Lifetime risk for diabetes mellitus in the United States. Diabetes 52: A225-A226, 2003.
34. Nordt TK, Sawa H, Fujii S, Bode C, Sobel BE. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo. J Mol Cell Cardiol 30: 1535-1543, 1998.
35. Park SH, Marso SP, Zhou ZM, Foroudi F, Topol EJ, Lincoff AM. Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation 104: 815-819, 2001.
36. Pearce CG, Najjar SF, Kapadia MR, Murar J, Eng J, Lyle B, Aalami OO, Jiang Q, Hrabie JA, Saavedra JE, Keefer LK, Kibbe MR. Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. Free Radic Biol Med 44: 73-81, 2008.
37. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2: 1057-1058, 1987. (Pubitemid 17154788)
38. Shaw S, Wang X, Redd H, Alexander GD, Isales CM, Marrero MB. High glucose augments the angiotensin II-induced activation of JAK2 in vascular smooth muscle cells via the polyol pathway. J Biol Chem 278: 30634-30641, 2003. (Pubitemid 36994568)
39. Shears LL, Kibbe MR, Murdock AD, Billiar TR, Lizonova A, Kovesdi I, Watkins SC, Tzeng E. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg 187: 295-306, 1998.
40. Shinozaki K, Suzuki M, Ikebuchi M, Hara Y, Harano Y. Demonstration of insulin resistance in coronary artery disease documented with angiography. Diabetes Care 19: 1-7, 1996. (Pubitemid 26006605)
41. Staiger K, Staiger H, Schweitzer M, Metzinger E, Balletshofer B, Haring HU, Kellerer M. Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia 48: 1898-1905, 2005.
42. Tzeng E, Kim YM, Pitt BR, Lizonova A, Kovesdi I, Billiar TR. Adenoviral transfer of the inducible nitric oxide synthase gene blocks endothelial cell apoptosis. Surgery 122: 255-263, 1997.
43. Wang C, Gurevich I, Draznin B. Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Diabetes 52: 2562-2569, 2003.
44. White MF. Insulin signaling in health and disease. Science 302: 1710-1711, 2003.
45. Zhuang D, Pu QH, Ceacareanu B, Chang YZ, Dixit M, Hassid A. Chronic insulin treatment amplifies PDGF-induced motility in differentiated aortic smooth muscle cells by suppressing the expression and function of PTP1B. Am J Physiol Heart Circ Physiol 295: H163-H173, 2008.
46. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P, Ledda F. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 94: 2036-2044, 1994.